1Bozzi Y, Casarosa S, Caleo M. Epilepsy as a neurodevelopmental disorder. Frontiers in psychiatry. 2012 Mar 19;3:19. doi: 10.3389/fpsyt.2012.00019.  

2Conrad J, Pawlowski M, Dogan M, et al. Seizures after cerebrovascular events: Risk factors and clinical features. Seizure. 2013;22(4):275-82. doi:10.1016/j.seizure.2013.01.014.

3Wang J, Lin ZJ, Liu L, Xu HQ, Shi YW, Yi YH, He N, Liao WP. Epilepsy-associated genes. Seizure. 2017 Jan 1;44:11-20. doi: 10.1016/j.seizure.2016.11.030.

4Hellwinkel JE, Anderson FL, Trofa DP, Deitrich MP, Dansby JD, Noble JM, Bottiglieri TS. Post-Traumatic Epilepsy after Sports-Related Concussion: A Case Report. Neurotrauma Reports. 2020 Jul 1;1(1):42-5.

5Arends JB. Movement‐based seizure detection. Epilepsia. 2018 Jun;59:30-5. doi: 10.1111/epi.14053

6Fogarasi A, Tuxhorn I, Janszky J, Janszky I, Rásonyi G, Kelemen A, Halász P. Age‐dependent seizure semiology in temporal lobe epilepsy. Epilepsia. 2007 Sep;48(9):1697-702. doi: 10.1111/j.1528-1167.2007.01129.x

7Lee SI, Kirby D. Absence seizure with generalized rhythmic delta activity. Epilepsia. 1988 Jun;29(3):262-7. doi: 10.1111/j.1528-1157.1988.tb03716.x

8Jenssen S, Gracely EJ, Sperling MR. How long do most seizures last? A systematic comparison of seizures recorded in the epilepsy monitoring unit. Epilepsia. 2006 Sep;47(9):1499-503. doi: 10.1111/j.1528-1167.2006.00622.x

9Greenfield Jr LJ. Molecular mechanisms of antiseizure drug activity at GABAA receptors. Seizure. 2013 Oct 1;22(8):589-600. doi: 10.1016/j.seizure.2013.04.015

10Bagshaw AP, Cavanna AE. Brain mechanisms of altered consciousness in focal seizures. Behavioural neurology. 2011 Jan 1;24(1):35-41. doi: 10.3233/BEN-2011-0312

11Wiebe S, Blume WT, Girvin JP, Eliasziw M. A randomized, controlled trial of surgery for temporal-lobe epilepsy. New England Journal of Medicine. 2001 Aug 2;345(5):311-8. doi: 10.1056/NEJM200108023450501

12Pohlmann-Eden B, Beghi E, Camfield C, Camfield P. The first seizure and its management in adults and children. Bmj. 2006 Feb 9;332(7537):339-42. doi: 10.1136/bmj.332.7537.339

13Bozzi Y, Provenzano G, Casarosa S. Neurobiological bases of autism–epilepsy comorbidity: a focus on excitation/inhibition imbalance. European Journal of Neuroscience. 2018 Mar;47(6):534-48. doi: 10.1111/ejn.13595

14Porter RJ, Kupferberg HJ, Hessie BJ. Mechanisms of action of anti-seizure drugs and the anticonvulsant screening program of the National Institute of Neurological Disorders and Stroke. Int J Clin Pharmacol Ther. 2015 Jan 1;53:9-12. doi: 10.5414/CP202212.

15Kalis MM, Huff NA. Oxcarbazepine, an antiepileptic agent. Clinical therapeutics. 2001 May 1;23(5):680-700. doi: 10.1016/s0149-2918(01)80019-9. 

16Zou S, Kumar U. Cannabinoid receptors and the endocannabinoid system: signaling and function in the central nervous system. International journal of molecular sciences. 2018 Mar;19(3):833. doi: 10.3390/ijms19030833

17Gu B, Zhu M, Glass MR, Rougié M, Nikolova VD, Moy SS, Carney PR, Philpot BD. Cannabidiol attenuates seizures and EEG abnormalities in Angelman syndrome model mice. The Journal of clinical investigation. 2019 Nov 4;129(12). doi: 10.1172/JCI130419

18Devinsky O, Patel AD, Cross JH, Villanueva V, Wirrell EC, Privitera M, Greenwood SM, Roberts C, Checketts D, VanLandingham KE, Zuberi SM. Effect of cannabidiol on drop seizures in the Lennox–Gastaut syndrome. New England Journal of Medicine. 2018 May 17;378(20):1888-97. doi: 10.1056/NEJMoa1714631

19Devinsky O, Cilio MR, Cross H, Fernandez‐Ruiz J, French J, Hill C, Katz R, Di Marzo V, Jutras‐Aswad D, Notcutt WG, Martinez‐Orgado J. Cannabidiol: pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders. Epilepsia. 2014 Jun;55(6):791-802. doi: 10.1111/epi.12631